Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 OctoPlus Inks Delivery Pact with U.S. Biotech | Contract Pharma

What are you searching for?

Sign in
Breaking News

OctoPlus Inks Delivery Pact with U.S. Biotech

OctoPlus N.V. has signed an agreement with an undisclosed U.S. biotechnology company for the use of OctoPlus' controlled release technology.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

OctoPlus N.V. has signed an agreement with an undisclosed U.S. biotechnology company for the use of OctoPlus’ controlled release technology. OctoPlus will use its PolyActive drug delivery technology to develop a controlled release version of a product currently in clinical development.

Simon Sturge, chief executive officer of OctoPlus, said, “I am delighted to see the continued adoption of our PolyActive technology. We continue to explore opportunities where OctoPlus’ unique skills in microsphere development and production can be best exploited.” Financial terms were not disclosed.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics